The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,007
Radiologically isolated syndrome and multiple sclerosis
Yamout, B., & Khawajah, M. A. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.08.016 · Cited by 45
Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review
Manca, R., Sharrack, B., Paling, D., Wilkinson, I. D., & Venneri, A. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.03.003 · Cited by 45
Ozanimod for the treatment of relapsing remitting multiple sclerosis
Rasche, L., & Paul, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1540592 · Cited by 43
The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases
Herden, L., & Weissert, R. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00133 · Cited by 46
Prostaglandins as the Agents That Modulate the Course of Brain Disorders
Famitafreshi, H., & Karimian, M. (2020) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s240800 · Cited by 44
Occupational performance in multiple sclerosis and its relationship with quality of life and fatigue
Pérez‐de‐Heredia‐Torres, M., Hoyas, E. H., Sánchez‐Camarero, C., Máximo-Bocanegra, N., Ayala, J., Sánchez-Herrera-Baeza, P., Martínez-Piédrola, R. M., García‐Bravo, C., Mayoral-Martín, A., & Serrada-Tejeda, S. (2020) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.20.05914-6 · Cited by 43
Calabresi, P. A., Arnold, D. L., Sangurdekar, D. P., Singh, C. M., Altincatal, A., de Moor, C., Engle, B., Goyal, J., Deykin, A., Szak, S. T., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520972573 · Cited by 43
Self-citationDahlke, F., Arnold, D. L., Aarden, P., Ganjgahi, H., Häring, D. A., Čuklina, J., Nichols, T. E., Gardiner, S., Bermel, R. A., & Wiendl, H. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520988637 · Cited by 43
Hecker, M., Fitzner, B., Jäger, K., Bühring, J., Schwartz, M., Hartmann, A., Walter, M., & Zettl, U. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02315-y · Cited by 43
Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Geladaris, A., Häusler, D., & Weber, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073461 · Cited by 44
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
Vasincu, A., Rusu, R.-N., Ababei, D. C., Larion, M., Bild, W., Stanciu, G. D., Solcan, C., & Bild, V. (2022) · Biology · doi:10.3390/biology11030440 · Cited by 44
Fisher, P., Salmon, P., Heffer-Rahn, P., Huntley, C., Reilly, J., & Cherry, M. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.073 · Cited by 42
Multiple Sclerosis and Aging: The Dynamics of Demyelination and Remyelination
Correale, J. D., & Ysrraelit, M. C. (2022) · ASN NEURO · doi:10.1177/17590914221118502 · Cited by 45
Sharmin, S., Roos, I., Malpas, C. B., Iaffaldano, P., Simone, M., Filippi, M., Havrdová, E., Özakbaş, S., Morra, V. B., Alroughani, R., et al. (2024) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(24)00047-6 · Cited by 42
Self-citationYi, X., Zhang, Y., Du, Q., Kang, J. F., Song, S., Li, T., & Jiang, Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1457788 · Cited by 42
Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología
Merino, A. G., Ara, J. R., Fernández, Ó., Pascual, L. L., Torres, E. M., & Zarrantz, A. R.-A. (2016) · Neurología · doi:10.1016/j.nrl.2016.02.026 · Cited by 42
Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis
Burgetová, A., Dušek, P., Vaněčková, M., Horakova, D., Langkammer, C., Krásenský, J., Sobíšek, L., Matras, P., Mašek, M., & Seidl, Z. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5166 · Cited by 43
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
Afolabi, D., Albor, C., Zalewski, L., Altmann, D. R., Baker, D., & Schmierer, K. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517726380 · Cited by 42
The Emerging Role of Zinc in the Pathogenesis of Multiple Sclerosis
Choi, B. Y., Jung, J., & Suh, S. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102070 · Cited by 43
Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
Saluk, J., Dziedzic, A., & Bijak, M. (2019) · Cells · doi:10.3390/cells8020110 · Cited by 42
Differentiating societal costs of disability worsening in multiple sclerosis
Neß, N.-H., Schriefer, D., Haase, R., Ettle, B., Cornelissen, C., & Ziemssen, T. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09676-4 · Cited by 42
Sheikh, M. H., Henson, S. M., Loiola, R. A., Mercurio, S., Colamatteo, A., Maniscalco, G. T., Rosa, V. D., McArthur, S., & Solito, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01810-8 · Cited by 42
Louis, E. D., Huey, E. D., & Cosentino, S. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.08.017 · Cited by 42
Pontillo, G., Penna, S., Cocozza, S., Quarantelli, M., Gravina, M., Lanzillo, R., Marrone, S., Costabile, T., Inglese, M., Morra, V. B., et al. (2022) · European Radiology · doi:10.1007/s00330-022-08610-z · Cited by 44
Self-citationSpelman, T. D., Özakbaş, S., Alroughani, R., Terzi, M., Hodgkinson, S. J., Laureys, G., Kalinčík, T., van der Walt, A., Yamout, B., Lechner‐Scott, J., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221137502 · Cited by 41
Boffa, G., Signori, A., Massacesi, L., Mariottini, A., Sbragia, E., Cottone, S., Amato, M. P., Gasperini, C., Moiola, L., Meletti, S., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000206750 · Cited by 41
Self-citationSinger, B. A., Feng, J. J., & Chiong-Rivero, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12305-4 · Cited by 43
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis
Androdias, G., Lünemann, J. D., Maillart, É., Amato, M. P., Audoin, B., Bruijstens, A. L., Bsteh, G., Butzkueven, H., Ciccarelli, O., Cobo‐Calvo, Á., et al. (2024) · Brain · doi:10.1093/brain/awae409 · Cited by 41
Self-citationPasquali, L., Pecori, C., Lucchesi, C., LoGerfo, A., Iudice, A., Siciliano, G., & Bonuccelli, U. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.09.024 · Cited by 41
D’Amico, E., Patti, F., Zanghì, A., & Zappia, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101725 · Cited by 41
Siponimod for the treatment of secondary progressive multiple sclerosis
Dumitrescu, L., Constantinescu, C. S., & Tănăsescu, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551363 · Cited by 41
Fatigue and Suicidal Ideation in People With Multiple Sclerosis: The Role of Social Support
Mikula, P., Timková, V., Linkova, M., Vitková, M., Szilasiová, J., & Nagyová, I. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.00504 · Cited by 41
Kwiatkowski, A. J., Stewart, J. M., Cho, J. J., Avram, D., & Keselowsky, B. G. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000164 · Cited by 43
Petzold, A., Coric, D., Balk, L. J., Hamann, S., Uitdehaag, B. M. J., Denniston, A. K., Keane, P. A., & Crabb, D. P. (2020) · Annals of Neurology · doi:10.1002/ana.25782 · Cited by 41
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
Capasso, N., Nozzolillo, A., Scalia, G., Lanzillo, R., Carotenuto, A., Angelis, M. D., Petruzzo, M., Saccà, F., Russo, C. V., Morra, V. B., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102802 · Cited by 42
Relapse-independent multiple sclerosis progression under natalizumab
Graf, J., Leussink, V. I., Soncin, G., Lepka, K., Meinl, I., Kümpfel, T., Meuth, S. G., Hartung, H., Havla, J. B., Aktaş, O., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab229 · Cited by 41
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis
Cohen, J. A., LUBLIN, F. D., Lock, C., Pelletier, D., Chitnis, T., Mehra, M., Gothelf, Y., Aricha, R., Lindborg, S. R., Lebovits, C., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221122156 · Cited by 41
Self-citationElectroencephalography-Derived Sensory and Motor Network Topology in Multiple Sclerosis Fatigue
Vecchio, F., Miraglia, F., Porcaro, C., Cottone, C., Cancelli, A., Rossini, P. M., & Tecchio, F. (2016) · Neurorehabilitation and neural repair · doi:10.1177/1545968316656055 · Cited by 41
Third wave cognitive behavioural therapies for people with multiple sclerosis: a scoping review
Zarotti, N., Eccles, F., Broyd, A., Longinotti, C., Mobley, A., & Simpson, J. (2023) · Disability and Rehabilitation · doi:10.1080/09638288.2022.2069292 · Cited by 40
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
Marziniak, M., & Meuth, S. G. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0149-1 · Cited by 40
Studer, V., Rocchi, C., Motta, C., Lauretti, B., Perugini, J., Brambilla, L., Gutierrez, L. P., Camera, G., Barbieri, F. R., Marfia, G. A., et al. (2017) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217317701317 · Cited by 40
Multiple Sclerosis and Exercise: A Literature Review
Reynolds, E. R., Ashbaugh, A., Hockenberry, B. J., & McGrew, C. A. (2018) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000446 · Cited by 40
Role of Peripheral Immune Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Dhaiban, S., Al‐Ani, M., Elemam, N. M., Al-Aawad, M. H., Al-Rawi, Z., & Maghazachi, A. A. (2021) · Sci · doi:10.3390/sci3010012 · Cited by 40
The Dichotomous Role of Inflammation in the CNS: A Mitochondrial Point of View
Vezzani, B., Carinci, M., Patergnani, S., Pasquin, M., Guarino, A., Aziz, N., Pinton, P., Simonato, M., & Giorgi, C. (2020) · Biomolecules · doi:10.3390/biom10101437 · Cited by 40
Torres, J. B., Roodselaar, J., Sealey, M. A., Ziehn, M. O., Bigaud, M., Kneuer, R., Leppert, D., Weckbecker, G., Cornelissen, B. T., & Anthony, D. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814064 · Cited by 41
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
Lucchini, M., Arcangelis, V. D., Piro, G., Nociti, V., Bianco, A. D., Fino, C. D., Sante, G. D., Ria, F., Calabresi, P., & Massimiliano Mirabella, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03060-6 · Cited by 40
Self-citationDysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients
Bari, M. D., Reale, M., Nicola, M. D., Orlando, V., Galizia, S., Porfilio, I., Costantini, E., D’Angelo, C., Ruggieri, S., Biagioni, S., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122009 · Cited by 40
Seasonal variation in multiple sclerosis relapse
Harding, K. E., Tilling, K. M., MacIver, C., Willis, M., Joseph, F., Ingram, G., Hirst, C. L., Wardle, M., Pickersgill, T. P., Ben‐Shlomo, Y., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8485-0 · Cited by 40
Assessing disease progression and treatment response in progressive multiple sclerosis
Comı, G., Costa, G. D., Stankoff, B., Hartung, H., Sørensen, P. S., Vermersch, P., & Leocani, L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01006-1 · Cited by 42
Self-citationUric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study
Moccia, M., Lanzillo, R., Costabile, T., Russo, C. V., Carotenuto, A., Sasso, G., Postiglione, E., Picione, C. D. L., Vastola, M., Maniscalco, G. T., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7666-y · Cited by 39
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
Sellebjerg, F. T., Cadavid, D., Steiner, D., Villar, L. M., Reynolds, R., & Mikol, D. D. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615615257 · Cited by 45
Kremer, I., Evers, S., Jongen, P. J., van der Weijden, T., van de Kolk, I., & Hiligsmann, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164862 · Cited by 39
Boyko, A. N., & Gusev, E. I. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171172292-106 · Cited by 39
Beier, M. L., Gromisch, E. S., Hughes, A. J., Alschuler, K. N., Madathil, R. L., Chiaravalloti, N. D., & Foley, F. W. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.019 · Cited by 39
Frahm, N., Hecker, M., & Zettl, U. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-40283-5 · Cited by 40
Ziemssen, T., Tolley, C., Bennett, B., Kilgariff, S., Jones, E., Pike, J., Tomic, D., Piani-Meier, D., & Lahoz, R. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101861 · Cited by 39
Non-invasive quantification of inflammation, axonal and myelin injury in multiple sclerosis
Schiavi, S., Petracca, M., Sun, P., Fleysher, L., Cocozza, S., Mendili, M. M. E., Signori, A., Babb, J. S., Podranski, K., Song, S., et al. (2020) · Brain · doi:10.1093/brain/awaa381 · Cited by 40
Self-citationSystematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
Bühring, J., Hecker, M., Fitzner, B., & Zettl, U. K. (2021) · Aging and Disease · doi:10.14336/ad.2021.0106 · Cited by 39
The “mitochondrial stress responses”: the “Dr. Jekyll and Mr. Hyde” of neuronal disorders
Rimessi, A., Patergnani, S., Morciano, G., Carinci, M., Leo, S., & Pinton, P. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.339473 · Cited by 41
Secondary Progressive Multiple Sclerosis: Definition and Measurement
Plantone, D., Angelis, F. D., Doshi, A., & Chataway, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0340-9 · Cited by 39
Overcoming Immune Dysregulation with Immunoengineered Nanobiomaterials
Scott, E. A., Karabin, N. B., & Augsornworawat, P. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044603 · Cited by 39
The transitional phase of multiple sclerosis: Characterization and conceptual framework
Kleiter, I., Ayzenberg, I., Havla, J. B., Lukas, C., Penner, I., Stadelmann, C., & Linker, R. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102242 · Cited by 38
Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis
Blagov, A. V., Sukhorukov, V. N., Orekhov, A. N., Sazonova, M. A., & Melnichenko, A. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112725 · Cited by 41
The association between brain volume loss and disability in multiple sclerosis: A systematic review
Matthews, P. M., Gupta, D., Mittal, D., Bai, W., Scalfari, A., Pollock, K. G., Sharma, V., & Hill, N. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104714 · Cited by 38
Zainab, S. R., Khan, J., Tipu, M. K., Jahan, F., & Irshad, N. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.029 · Cited by 44
Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis
Friess, J., Hecker, M., Roch, L., Koczan, D., Fitzner, B., Angerer, I. C., Schröder, I., Flechtner, K., Thiesen, H., Winkelmann, A., et al. (2017) · Scientific Reports · doi:10.1038/srep42087 · Cited by 41
Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan
Niino, M., Fukazawa, T., Kira, J., Okuno, T., Mori, M., Sanjo, N., Ohashi, T., Fukaura, H., Fujimori, J., Shimizu, Y., et al. (2017) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217317748972 · Cited by 38
Predicting the profile of increasing disability in multiple sclerosis
Tomassini, V., Fanelli, F., Prosperini, L., Cerqua, R., Cavalla, P., & Pozzilli, C. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518790397 · Cited by 40
Self-citationGeraci, F., Ragonese, P., Barreca, M. M., Aliotta, E., Mazzola, M. A., Realmuto, S., Vazzoler, G., Savettieri, G., Sconzo, G., & Salemi, G. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00418 · Cited by 38
The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions
Rojas, J. I., Carrá, A., Correale, J. D., Cristiano, E., Liguori, N. F., Alonso, R. N., Pinheiro, A. A., Balbuena, M. E., Barboza, A. G., Bestoso, S., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.05.004 · Cited by 38
Kunkl, M., Sambucci, M., Ruggieri, S., Amormino, C., Tortorella, C., Gasperini, C., Battistini, L., & Tuosto, L. (2019) · Cells · doi:10.3390/cells8060575 · Cited by 39
Maple, P. A. C., Tănăsescu, R., Gran, B., & Constantinescu, C. S. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.017 · Cited by 38
Risk of MS relapse after yellow fever vaccination
Huttner, A., Éperon, G., Lascano, A. M., Roth, S., Schwob, J.-M., Siegrist, C., & Lalive, P. H. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000726 · Cited by 41
Boffa, G., Lapucci, C., Sbragia, E., Varaldo, R., Raiola, A. M., Currò, D., Roccatagliata, L., Capello, E., Laroni, A., Mikulska, M., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14324 · Cited by 39
Self-citationInhibition of neutral sphingomyelinase 2 promotes remyelination
Yoo, S.-W., Agarwal, A., Smith, M. D., Khuder, S. S., Baxi, E. G., Thomas, A. G., Rojas, C. J., Moniruzzman, M., Slusher, B. S., Bergles, D. E., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5210 · Cited by 38
Self-citationA Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
Frisch, E. S., Pretzsch, R., & Weber, M. S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01048-z · Cited by 39
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Häußler, V., Ufer, F., Pöttgen, J., Wolschke, C., Friese, M. A., Kröger, N., Heesen, C., & Stellmann, J. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51366 · Cited by 38
Structural and Functional Connectivity Substrates of Cognitive Impairment in Multiple Sclerosis
Zhang, J., Cortese, R., Stefano, N. D., & Giorgio, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.671894 · Cited by 38
Brand, J. S., Smith, K. A., Piehl, F., Olsson, T. P., & Montgomery, S. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100470 · Cited by 39
Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome
Rival, M., Galoppin, M., & Thouvenot, É. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.866092 · Cited by 41
Building a monitoring matrix for the management of multiple sclerosis
Voigt, I., Inojosa, H., Wenk, J., Akgün, K., & Ziemssen, T. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103358 · Cited by 40
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?
Bonenfant, J., Bajeux, E., Deburghgraeve, V., Page, E. L., Edan, G., & Kerbrat, A. (2016) · European Journal of Neurology · doi:10.1111/ene.13181 · Cited by 38
Gait pattern in patients with different multiple sclerosis phenotypes
Dujmović, I., Radovanovic, S. M., Martinović, V., Dackovic, J. R., Maric, G. D., Mesaroš, Š., Pekmezovic, T. D., Kostić, V., & Drulovic, J. S. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.01.012 · Cited by 38
Li, G., Yamasaki, R., Fang, M., Masaki, K., Ochi, H., Matsushita, T., & Kira, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20390-5 · Cited by 40
Pietroboni, A. M., Carandini, T., Colombi, A., Mercurio, M., Ghezzi, L., Giulietti, G., Scarioni, M., Arighi, A., Fenoglio, C., Riz, M. A. D., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4182-1 · Cited by 39
Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis
Clayton, B. L. L., Barbar, L., Sapar, M., Kalpana, K., Rao, C., Migliori, B., Rusielewicz, T., Paull, D., Brenner, K., Moroziewicz, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.08.002 · Cited by 38
Post‐mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms
Fransen, N. L., Crusius, J. B. A., Smolders, J., Mizee, M. R., van Eden, C. G., Luchetti, S., Remmerswaal, E. B. M., Hamann, J., Mason, M. R. J., & Huitinga, I. (2020) · Brain Pathology · doi:10.1111/bpa.12760 · Cited by 37
Relapsing and progressive MS: the sex-specific perspective
Rommer, P. S., Ellenberger, D., Hellwig, K., Haas, J., Pöhlau, D., Stahmann, A., Zettl, U. K., & on behalf of the Scientific Advisory Group of the German MS-Register by the German MS Society (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420956495 · Cited by 37
Montolío, A., Cegoñino, J., García‐Martín, E., & del Palomar, A. P. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-02930-3 · Cited by 42
Muris, A., Rolf, L., Broen, K., Hupperts, R., Damoiseaux, J. G. M. C., & Smolders, J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.11.009 · Cited by 37
Rodríguez, J., Cobo‐Calvo, Á., Villar, L. M., Munteis, E., Blanco, Y., Rasal, R., Vera, A., Muntasell, A., Álvarez‐Lafuente, R., Saiz, A., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515601215 · Cited by 37
Ibudilast for the treatment of multiple sclerosis
Goodman, A. D., Gyang, T. V., & Smith, A. D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221924 · Cited by 37
Self-citationRivas, J. R., Ireland, S. J., Chkheidze, R., Rounds, W. H., Lim, J. S., Johnson, J. T., Ramirez, D. M. O., Ligocki, A. J., Chen, D., Guzman, A. A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1627-0 · Cited by 37
Coret, F., Miralles, F. C. P., Gascón, F., Alcalá, C., Navarré, A., Bernad, A., Boscá, I., Escutia, M., Gil‐Perotín, S., & Casanova, B. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318783347 · Cited by 37
Chen, Y., Zhang, Z.-X., Zheng, L., Wang, L., Liu, Y.-F., Yin, W.-Y., Chen, Y., Wang, X., Hou, S., Chen, J., et al. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104490 · Cited by 37
Siponimod in the treatment of multiple sclerosis
Goodman, A. D., Anadani, N. A., & Gerwitz, L. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1676725 · Cited by 40
Self-citationClinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis
Bonacchi, R., Pagani, E., Meani, A., Cacciaguerra, L., Preziosa, P., Meo, E. D., Filippi, M., & Rocca, M. A. (2020) · Radiology · doi:10.1148/radiol.2020200430 · Cited by 40
Lizak, N., Malpas, C. B., Sharmin, S., Havrdová, E., Horáková, D., Izquierdo, G., Eichau, S., Lugaresi, A., Duquette, P., Girard, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2453 · Cited by 37
Evertsson, B., Hoyt, T., Christensen, A., Nimer, F. A., Foley, J. F., & Piehl, F. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217320964505 · Cited by 38
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis
Marastoni, D., Magliozzi, R., Bolzan, A., Pisani, A. I., Rossi, S., Crescenzo, F., Montemezzi, S., Pizzini, F. B., & Calabrese, M. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001083 · Cited by 39
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
